Sabra Healthcare REIT (NASDAQ:SBRA) Issues Earnings Results, Beats Estimates By $0.01 EPS

Sabra Healthcare REIT (NASDAQ:SBRAGet Free Report) issued its quarterly earnings data on Thursday. The real estate investment trust reported $0.38 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.01, Zacks reports. Sabra Healthcare REIT had a net margin of 23.50% and a return on equity of 6.38%. The firm had revenue of $201.35 million for the quarter, compared to the consensus estimate of $201.97 million. During the same period last year, the firm posted $0.36 EPS. Sabra Healthcare REIT’s quarterly revenue was up 16.2% compared to the same quarter last year. Sabra Healthcare REIT updated its FY 2026 guidance to 1.550-1.590 EPS.

Sabra Healthcare REIT Stock Performance

NASDAQ:SBRA traded up $0.65 during mid-day trading on Thursday, hitting $20.25. 5,080,914 shares of the stock were exchanged, compared to its average volume of 2,810,294. The company has a debt-to-equity ratio of 0.92, a quick ratio of 5.19 and a current ratio of 5.19. The stock has a market capitalization of $5.05 billion, a price-to-earnings ratio of 28.13 and a beta of 0.67. Sabra Healthcare REIT has a fifty-two week low of $15.60 and a fifty-two week high of $20.27. The firm’s 50-day simple moving average is $19.00 and its 200 day simple moving average is $18.74.

Sabra Healthcare REIT Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 27th. Shareholders of record on Friday, February 13th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 5.9%. The ex-dividend date of this dividend is Friday, February 13th. Sabra Healthcare REIT’s payout ratio is 166.67%.

Hedge Funds Weigh In On Sabra Healthcare REIT

Several institutional investors and hedge funds have recently added to or reduced their stakes in SBRA. Balyasny Asset Management L.P. bought a new stake in Sabra Healthcare REIT in the second quarter valued at approximately $49,955,000. Nuveen LLC raised its stake in shares of Sabra Healthcare REIT by 28.6% during the 4th quarter. Nuveen LLC now owns 7,303,254 shares of the real estate investment trust’s stock worth $138,324,000 after purchasing an additional 1,625,072 shares during the period. Qube Research & Technologies Ltd raised its stake in shares of Sabra Healthcare REIT by 856.5% in the second quarter. Qube Research & Technologies Ltd now owns 1,398,965 shares of the real estate investment trust’s stock valued at $25,797,000 after buying an additional 1,252,708 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Sabra Healthcare REIT by 65.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,480,576 shares of the real estate investment trust’s stock valued at $46,982,000 after purchasing an additional 985,211 shares during the period. Finally, Millennium Management LLC lifted its holdings in Sabra Healthcare REIT by 141.4% during the 3rd quarter. Millennium Management LLC now owns 897,087 shares of the real estate investment trust’s stock worth $16,722,000 after purchasing an additional 525,480 shares in the last quarter. Institutional investors own 99.40% of the company’s stock.

Wall Street Analyst Weigh In

SBRA has been the subject of several recent analyst reports. UBS Group began coverage on shares of Sabra Healthcare REIT in a report on Tuesday, November 18th. They issued a “neutral” rating and a $20.00 price objective for the company. Wells Fargo & Company lifted their price target on Sabra Healthcare REIT from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Tuesday, November 25th. National Bank Financial set a $22.00 target price on Sabra Healthcare REIT in a report on Friday, October 17th. Wall Street Zen cut Sabra Healthcare REIT from a “hold” rating to a “sell” rating in a research report on Friday, January 23rd. Finally, Truist Financial raised their price objective on Sabra Healthcare REIT from $20.00 to $21.00 and gave the company a “hold” rating in a research note on Tuesday, January 20th. Four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Sabra Healthcare REIT presently has a consensus rating of “Hold” and a consensus price target of $21.11.

Read Our Latest Stock Report on SBRA

About Sabra Healthcare REIT

(Get Free Report)

Sabra Healthcare REIT, Inc (NASDAQ: SBRA) is a real estate investment trust that acquires, owns and operates net?lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long?term, triple?net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.

Serving a broad spectrum of care segments, Sabra’s tenants include both regional and national providers of assisted living, independent living, memory care, post?acute rehabilitation and research and development laboratories.

Further Reading

Earnings History for Sabra Healthcare REIT (NASDAQ:SBRA)

Receive News & Ratings for Sabra Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sabra Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.